[go: up one dir, main page]

MX2024001577A - Terapia genica aqp1 para prevenir la hipofuncion salival inducida por radiacion. - Google Patents

Terapia genica aqp1 para prevenir la hipofuncion salival inducida por radiacion.

Info

Publication number
MX2024001577A
MX2024001577A MX2024001577A MX2024001577A MX2024001577A MX 2024001577 A MX2024001577 A MX 2024001577A MX 2024001577 A MX2024001577 A MX 2024001577A MX 2024001577 A MX2024001577 A MX 2024001577A MX 2024001577 A MX2024001577 A MX 2024001577A
Authority
MX
Mexico
Prior art keywords
aqp1
gene therapy
radiation induced
prevent radiation
hypofunction
Prior art date
Application number
MX2024001577A
Other languages
English (en)
Inventor
John A Chiorini
Matthew P Hoffman
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2024001577A publication Critical patent/MX2024001577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La administración de ácido desoxirribonucleico complementario (ADNc) a acuaporina 11 (AQP1) a una glándula salival antes del tratamiento con radiación ionizante (IR) previene la pérdida función posterior inducida por IR. La administración de AQP1 (por ejemplo, AQP1 humana; hAQP1, antes del tratamiento con IR (por ejemplo, en pacientes cáncer de cabeza y cuello) puede reducir o prevenir la hipofunción salival inducida por IR, dando como resultado una producción salival elevada.
MX2024001577A 2021-08-04 2022-08-04 Terapia genica aqp1 para prevenir la hipofuncion salival inducida por radiacion. MX2024001577A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229279P 2021-08-04 2021-08-04
US202263297342P 2022-01-07 2022-01-07
PCT/US2022/074559 WO2023015269A1 (en) 2021-08-04 2022-08-04 Aqp1 gene therapy to prevent radiation induced salivary hypofunction

Publications (1)

Publication Number Publication Date
MX2024001577A true MX2024001577A (es) 2024-04-22

Family

ID=83598573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001577A MX2024001577A (es) 2021-08-04 2022-08-04 Terapia genica aqp1 para prevenir la hipofuncion salival inducida por radiacion.

Country Status (10)

Country Link
US (1) US20240335506A1 (es)
EP (1) EP4380593A1 (es)
JP (1) JP2024528997A (es)
KR (1) KR20240049295A (es)
AU (1) AU2022325158A1 (es)
BR (1) BR112024002194A2 (es)
CA (1) CA3227584A1 (es)
IL (1) IL310485A (es)
MX (1) MX2024001577A (es)
WO (1) WO2023015269A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882763C (en) * 2012-08-31 2019-01-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav mediated aquaporin gene transer to treat sjogren's syndrome
EP3294894B8 (en) 2015-05-12 2019-09-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone

Also Published As

Publication number Publication date
AU2022325158A1 (en) 2024-03-14
IL310485A (en) 2024-03-01
BR112024002194A2 (pt) 2024-04-30
CA3227584A1 (en) 2023-02-09
WO2023015269A1 (en) 2023-02-09
JP2024528997A (ja) 2024-08-01
US20240335506A1 (en) 2024-10-10
KR20240049295A (ko) 2024-04-16
EP4380593A1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
NO971355L (no) Fotodynamiske terapi i selektiv celleinaktivering i blod og behandling av immundysfunksjons-sykdommer
CY1107143T1 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
NO20032027D0 (no) Effektive antitumorbehandlinger
DK1165108T3 (da) Anvendelse af et ekstrakt af Serenoa repens til fremstilling af et lægemiddel til behandling af prostatacancer
DE69330032D1 (de) Therapeutisches kombinationspräparat enthaltend interferon
EP4523745A3 (en) Bis-choline tetrathiomolybdate for treating wilson disease
BRPI0418157A (pt) terapêutica de tumores alogênicos
EP4289475A3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
AU2020327022A8 (en) Method of treating cancer
MX2024001577A (es) Terapia genica aqp1 para prevenir la hipofuncion salival inducida por radiacion.
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.
MX2019008076A (es) Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
PH12021550656A1 (en) Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
EP4545066A3 (en) 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
CN108066688A (zh) 一种用于火炙疗法的麝香蔴练灯火灸
Vervoort Evaluating the World Heart Federation’s 25 by 25: the forgotten millions
Hadi et al. Multifunctional dynamic toolbox: cordycepin plays a therapeutic role in various disorders
WO2019152343A8 (en) Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal)
US20200113778A1 (en) Biophotonic mask instrument and controlling method thereof
Falahzadeh et al. Comparison of Single-Channel and Multi-Channel Cochlear Implants in Terms of Encoding Strategy and Speech Understanding: A Systematic Review
Kochetov et al. The use of low-energy laser radiation in the combined treatment of patients with acute pneumonia
WO2022240804A3 (en) Methods of treating sickle cell disorder and related conditions